Premium
Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159
Author(s) -
Ryall R. D. H.,
Hanham I. W. F.,
Newton K. A.,
Hellmann K.,
Brinkley Diana M.,
Hjertaas O. K.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197410)34:4<1040::aid-cncr2820340413>3.0.co;2-5
Subject(s) - medicine , soft tissue , radiation therapy , toxicity , oncology , surgery
In a pilot clinical assessment of combined radiotherapy with the antimitotic agent ICRF 159, a good response was obtained in 18 of 22 patients (82%) with soft tissue and bone sarcomas. Six patients had complete regressions and 12 had regressions of 50% or more. Two had regressions of less than 50% and only 2 showed no response. Severe toxicity requiring interruption of treatment was not observed, but skin reactions were greater than expected. No lung reactions were seen. The combination appears to be synergistic.